Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 13/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HCK | P08631 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | PRKDC | P78527 | 2/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20263159 | 0.90 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL30280478 | 0.90 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263246 | 0.90 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL30280460 | 0.90 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263160 | 0.90 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263171 | 0.85 | CFTR (0.84) | CFTRPIK3CDSRCABL1EGFR | |
| SCHEMBL30280506 | 0.85 | CFTR (0.84) | CFTRPIK3CDSRCABL1EGFR | |
| SCHEMBL28981692 | 0.85 | CFTR (0.74) | CFTR | |
| SCHEMBL20162652 | 0.85 | CFTR (0.73) | CFTRSRCABL1EGFRKDR | |
| SCHEMBL20162654 | 0.85 | CFTR (0.73) | CFTRSRCABL1EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554506-B1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| EP-3554506-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| WO-2018112149-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATON THERAPEUTICS INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | CFTR 1/4885PIK3CD 653/4885SRC 2560/4885 |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RX3 | CFTR 1/4885PIK3CD 589/4885SRC 3243/4885 |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, SLC26A3, P2RY2 | CFTR 1/4885PIK3CD 653/4885SRC 2560/4885 |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | CFTR 1/4885PIK3CD 490/4885SRC 2852/4885 |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, P2RY2, P2RX5 | CFTR 1/4885PIK3CD 490/4885SRC 2852/4885 |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | CFTR 1/4885PIK3CD 490/4885SRC 2852/4885 |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | CFTR 1/4885PIK3CD 490/4885SRC 2852/4885 |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | CFTR 1/4885PIK3CD 653/4885SRC 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.